Dec 1, 2020

For Immediate Release December 1, 2020

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”),  a pharmaceutical company focused on the research, development and commercialization of  oncology and antiviral drugs, today announced that it has received the third tranche of funding  under the recently announced committed minimum financing of $2,000,000 with RB Capital  Partners Inc. This brings the total to $800,000 that the Company has received under this financing.  The proceeds will be used for the ongoing development of the Company’s Coronavirus Treatment  on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer  compound targeted for pancreatic cancer. 

Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, “We continue to be amazed  by both the ingenuity and the work ethic of Sunshine Biopharma’s leadership team. This is money  well spent as every dollar is dedicated to the understanding and advancement of life-saving  medicines. RB Capital is proud to invest in a company that is relentlessly working towards  developing a Coronavirus treatment. The implications of such a treatment are boundless.”  

Sunshine Biopharma Inc. CFO, Camille Sebaaly shared, “We have a lot of important work under  way, and the continued funding by RB Capital Partners enables us to keep our focus on the  advancement of our oncology and antiviral drugs. We look forward to continue working with them  as it is clear that they truly believe in our Company’s vision.”  

About Sunshine Biopharma’s Coronavirus Treatment 

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since  it first appeared in December 2019. There are currently no drugs that can effectively arrest  replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine  Biopharma filed a provisional patent application for several molecules which were designed by  computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of  the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such  molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of  Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM 

PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials  on COVID-19 patients.

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date  have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine  Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at  McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner  of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially  from those anticipated or expected, including statements related to the amount and timing of expected revenues  statements related to our financial performance, expected income, distributions, and future growth for upcoming  quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company  with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ  materially from those projected in or contemplated by the forward-looking statements due to a number of factors  detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain  growth or achieve profitability based upon many factors including but not limited to general stock market conditions.  Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have  incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines  noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long  term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s)  based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted  at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464